FDA approves Freenome's blood-based colorectal cancer screening test
Tweet Send to a Friend
Freenome (Nasdaq: FRNM) and Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration has approved SimpleScreen CRC, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
